PADDING
UNK
,
of
the
.
and
in
)
(
with
to
a
:
patients
that
for
gene
by
is
was
*
on
=
The
were
/
or
polymorphisms
as
polymorphism
cancer
expression
not
-
treatment
associated
response
an
genotype
be
In
study
1
%
are
alcohol
;
receptor
P
between
mutation
association
EGFR
cell
2
may
We
therapy
we
3
but
treated
cells
levels
significantly
A
after
activity
-induced
effects
from
clinical
inhibitor
genetic
+
have
which
allele
mice
this
than
dependence
risk
significant
CYP3A5
chemotherapy
dose
mutations
at
effect
these
<
results
CONCLUSIONS
increased
role
compared
kinase
has
higher
found
p
resistance
group
who
genotypes
among
human
RESULTS
also
genes
breast
n
variants
CONCLUSION
CYP2C19
promoter
To
protein
warfarin
did
showed
reduced
CYP2D6
CYP2C9
tacrolimus
-based
studies
METHODS
C
This
survival
population
combination
p53
subjects
CYP3A4
drug
advanced
efficacy
suggest
had
toxicity
metabolism
plasma
been
their
HER2
wild-type
mutant
sensitivity
status
mRNA
increase
factor
lung
NSCLC
transporter
Our
VKORC1
carriers
cocaine
single
chronic
concentrations
administration
both
plus
lower
TPMT
influence
model
growth
no
use
drugs
well
activation
exon
SNPs
[
inhibitors
serotonin
its
alleles
95
nucleotide
whether
]
other
SNP
tumors
Chinese
These
one
more
P450
cytochrome
HLA-B
BACKGROUND
-dependent
ABCB1
ratio
variability
nicotine
differences
present
MTHFR
induced
during
different
acid
dopamine
two
BRAF
only
high
control
COMT
including
against
first
pharmacokinetics
colorectal
4
concentration
Japanese
can
benefit
show
platinum
tamoxifen
functional
10
indicate
vivo
receiving
ribavirin
CI
major
clopidogrel
while
development
observed
function
controls
deficiency
data
lines
such
daily
when
previously
oral
irinotecan
line
women
>
decreased
findings
paclitaxel
evaluate
apoptosis
using
0
-positive
those
serum
blood
healthy
demonstrated
investigated
related
used
common
potential
might
hypersensitivity
based
transplant
within
6
type
involved
affect
years
-treated
haplotype
metastatic
erlotinib
all
responses
vitro
tyrosine
tumor
OBJECTIVE
whereas
either
Patients
examined
signaling
investigate
liver
analysis
heroin
presence
alone
II
inhibition
dehydrogenase
5-HTTLPR
reduction
KRAS
MDR1
variant
dependent
greater
respectively
hepatitis
recipients
exposure
variation
groups
mg
associations
first-line
target
age
deletion
low
into
important
predictor
region
homozygous
aspirin
agonist
doses
therapeutic
B
Association
-related
number
'
renal
MTX
changes
known
combined
overall
without
test
analyzed
ethanol
manner
thiopurine
could
5
predictive
acute
hepatic
adverse
reductase
maintenance
inhibited
disease
0.001
assessed
further
abacavir
susceptibility
pathway
following
genotyping
enzyme
Nrf2
standard
pharmacokinetic
OR
5701
studied
phase
demonstrate
mean
5-FU
induction
-mediated
AND
agents
epidermal
cases
carrying
through
conclusion
determine
trial
novel
expressed
imatinib
T
0.05
cancers
outcomes
I
clearance
our
melanoma
rat
h
interindividual
it
shown
suggesting
identified
progression-free
12
contrast
proliferation
leukemia
effective
early
measured
However
do
CpG
level
coronary
impact
-mutant
5-fluorouracil
frequency
synthase
reported
enzymes
CC
8
UGT1A1
Although
useful
aim
DNA
azathioprine
IL28B
smoking
specific
addiction
interaction
transplantation
rates
rate
detected
disposition
S
estrogen
better
methylation
No
induces
brain
increases
anti-
relation
channel
CYP2A6
Using
c-fos
appears
screening
value
cohort
via
odds
activated
haplotypes
's
9
neurons
kidney
encoding
virus
molecular
patient
beta
sensitive
genotyped
normal
men
relationship
vs.
doxorubicin
metabolic
abuse
lansoprazole
contribute
behavioral
factors
receptors
r
area
highly
lithium
regulatory
driven
similar
reduces
nucleus
poor
trastuzumab
vitamin
influenced
play
current
C3435T
sustained
time
cyclophosphamide
cellular
ITPA
risperidone
because
CBZ
anthracycline
7
syndrome
cetuximab
inhibiting
regimen
support
potent
It
PIK3CA
ratios
assay
review
populations
African
PURPOSE
oxide
difference
docetaxel
less
outcome
under
events
primary
oxaliplatin
methamphetamine
parameters
assess
Val
hypothesis
adjuvant
followed
Moreover
affected
metabolizers
evaluated
Phase
nitric
-resistant
multiple
single-nucleotide
subunit
revealed
There
individuals
testing
cholesterol
GABRA2
determined
individual
pharmacodynamic
ligand
resistant
interactions
expressing
SVR
system
CYP2B6
predict
c-Fos
confidence
glucose
anxiety
considered
cyclosporine
SLCO1B1
ALK
adenosine
clinically
DRD2
KIT
"
peginterferon
strong
mg/kg
affects
carcinoma
baseline
AD
schizophrenia
ovarian
substitution
CYP4F2
some
occurrence
analyses
arsenic
0.03
accumulation
virological
interval
40
C677T
established
prognostic
relapse
included
correlated
body
addition
phosphorylation
death
proteins
required
5-HTT
antagonist
extracellular
crizotinib
Genetic
AUC
platelet
seen
weight
harboring
Cancer
possible
regression
change
additional
per
gefitinib
ABCG2
there
metabolites
morphine
responsible
non-small
prior
methotrexate
developed
received
if
SIRT1
DPYD
CREB
BRCA1
locally
before
post-
celecoxib
active
four
extensive
HFE
0.01
stage
haloperidol
selection
16
ERCC1
asthma
Polymorphisms
complex
SJS
prostate
lipid
phenotype
ability
i.e.
weeks
thymidylate
1B
injection
endothelial
-mutated
depressive
recurrence
drinking
microg
versus
iron
AIMS
TEN
marker
any
seem
infection
CHC
Arg
days
opioid
persistent
binding
6-mercaptopurine
enhanced
comparison
male
damage
28
several
particularly
previous
small
improved
Therefore
lead
curve
knockout
glutathione
however
tandem
selected
enhances
large
GSTP1
requirements
Val158Met
ADH1B
Here
directed
metabolized
COX-2
models
vemurafenib
responded
N
non-small-cell
PFS
When
pretreatment
disorders
least
trend
interferon
dose-dependent
purpose
elimination
ALL
injury
severe
hypothesized
part
gemcitabine
MET
showing
profile
total
DAT
suggested
caused
content
evidence
disorder
stable
estradiol
prevalence
1G
likely
angiotensin
coding
reactions
respond
encoded
and/or
urinary
will
cisplatin
VNTR
due
tested
result
confer
diet
One
TNF-alpha
lapatinib
HIV-1
concentration-time
finding
toward
mechanisms
volunteers
mechanism
11
homozygotes
vascular
27
Among
metabolizing
inhibits
affecting
year
plasmid
Fos
should
cardiac
American
capecitabine
insulin
agent
dyskinesia
polymorphic
adjusted
characteristics
Pharmacogenetics
receive
muscle
rt
lipase
direct
Caucasian
mouse
performance
radiation
impaired
fact
childhood
although
2A
III
ER
hematopoietic
Effects
organic
correlation
MDR-1
probe
recent
randomized
secretion
reward
predicts
prevented
pharmacological
epoxide
transcriptional
subset
diabetes
17
JAK2
pancreatic
variable
APAP
self-administration
distribution
toxic
b
promoted
CFTR
even
most
inhibit
D
S-methyltransferase
MCL
isoform
alterations
adrenergic
hormone
-associated
CYP3A
pharmacodynamics
each
GSTT1
oncogene
correlate
tissues
decrease
months
CYP2C8
HO-1
improve
PEG-IFN
pharmacogenetic
substrate
possibly
tissue
preclinical
authors
-specific
ERK1/2
examine
member
fentanyl
does
vs
20
poorer
exhibited
orally
involvement
histone
Resistance
statins
regardless
same
clear
include
P-gp
targeted
sequencing
epithelial
suicide
A118G
depletion
provided
alpha
GSTM1
pattern
case
Lung
RBV
domain
colon
thrombosis
metformin
rs9934438
carboplatin
glutamate
where
antigen
lesions
provides
independent
rs9923231
primarily
day
predicting
non-
CD4
located
cAMP
recently
carried
history
Cyclin
ACE
capacity
favorable
degree
hydroxylation
hydroxylase
whose
profiles
rs2108622
isolates
adult
MEK1/2
BDNF
indicating
50
XRCC1
thus
intraperitoneal
pathways
activities
action
reverse
chemotherapeutic
dosage
formation
influences
triglyceride
regions
homocysteine
work
Effect
achieve
Group
HLA-A
membrane
uptake
lack
viral
determinants
inosine
safety
mesylate
MLL
15:02
TKI
unresectable
European
ADH2
alter
strongly
continued
CYP
c-myc
preference
three
explore
75
towards
TT
performed
heterozygotes
neoadjuvant
shows
induce
frequencies
Furthermore
EPHX1
Korean
relevant
tumour
targets
Breast
AZA
report
myelosuppression
L
atherosclerosis
ARE
HLA-C
appear
TKIs
Z
Since
down-regulates
dynamics
carrier
100
antiapoptotic
UNASSIGNED
sample
DESIGN
decreases
pharmacogenetics
selective
week
doublet
bone
protective
worse
cytotoxicity
UGT1A9
suppression
immunization
Epidermal
US
antiplatelet
nicotinic
lowering
variations
Ras
kinases
AA
DRD4
RFC1
new
SLC6A4
ODN
losartan
series
determining
them
PPARalpha
mutants
52
triphosphate
Sp1
humans
150
follow-up
upstream
peptide
antidepressant
avoid
skin
acetylcholine
striatum
diminished
develop
PATIENTS
translocation
R-
properties
immediate
catechol-O-methyltransferase
median
pressure
month
CYP2A5
regulate
c.
tolerance
failed
immunity
duplication
lysine
bevacizumab
D4
markedly
behavior
K-ras
Americans
subfamily
negative
respect
constructs
cassette
synthetic
-overexpressing
tumours
30
XIAP
HLA-
Polymorphism
At
MDR
myelogenous
especially
-negative
heterozygous
peak
marked
codeine
elevated
negatively
reactivated
rs1057910
hepatotoxicity
Additionally
-expressing
alcoholism
fludarabine
IDH1
multidrug
administered
mitochondrial
understanding
craving
descent
start
gastric
V600E
identifying
partial
?
noted
Caucasians
place
acenocoumarol
oocytes
Japan
cADRs
according
Transplant
given
kinetics
-tolerant
point
WT
harbored
antitumor
modulate
dosing
restored
out
HCV
minor
subgroup
open-label
24
symptoms
males
61
psychosis
require
modest
K
t.i.d.
statistically
HIV
26
genetically
molecules
0.02
injections
After
dystonia
EGCG
NMDA
pilot
60
Mutations
steroid
six
much
antiretroviral
treatments
Tamoxifen
inositol
essential
trials
TS
Treatment
OS
molecule
family
arrest
clozapine
rechallenge
RFS
amphetamine
pfmdr1
experimental
smoke
stent
E2
linear
Depression
size
OBJECTIVES
Vemurafenib
overexpression
up-regulated
On
For
nevirapine
lamivudine
produced
CD8
OPRM1
ADRB2
-TKI
Lack
Results
differentiation
investigation
Hb
female
hippocampal
MGMT
-binding
FLT3
extracted
substrates
0.06
Met
phosphorylated
mediated
CCK
sulphonylureas
PXR
reaction
undergoing
ATM
placebo
Inhibitor
NPY
M184V
contributed
phenotyping
70
failure
pain
aggressive
MEK
index
meta-analysis
constitutive
provide
hemoglobin
regulates
/neu
enhancement
AR
mCRC
specificity
setting
incidence
initial
GGCX
positive
postmenopausal
norepinephrine
so
suggests
250
correlates
HR
R
NAT2
G
everolimus
phenylalanine
signs
.02
HBV
methylenetetrahydrofolate
PSA
indicated
Cyp51
PDYN
folate
0.26
dihydropyrimidine
An
paroxetine
B1
solid
release
second
TNBC
murine
deaminase
TOP2A
21
downstream
like
voriconazole
approved
together
pegylated
PD
preoperative
PTH
central
P50
distinct
thereby
3101
.04
loss
reporter
virologic
find
calcium
abnormalities
DA
myeloid
corresponding
TYMS
sirolimus
extent
hepatocellular
PPI
laboratory
allopurinol
seems
L858R
C/T
withdrawal
digoxin
nor
refractory
loss-of-function
PACAP
antibody
rs8099917
transferase
improves
NF-kappaB
improvement
particular
sorafenib
surface
MMP-2
C/D
Sorafenib
carry
Based
low-dose
memory
prospectively
Is
CYP1A1
upregulated
dabrafenib
TNF
plays
values
ADV
sensitization
CYP2E1
five
hypermethylation
consistent
phenotypes
extract
PEG
p21
intronic
secondary
nasal
aimed
iNOS
5-HT
missense
then
ABCC2
noncarriers
Thus
01
TLR9
identification
inhibitory
radiotherapy
they
percutaneous
lymphoma
transcriptase
focused
rise
LSZ
striatal
modulates
promising
ALDH2
abnormal
basis
transcription
Tacrolimus
carbamazepine
yet
14
Maintenance
13
Previous
dexamethasone
CHFR
efavirenz
androgen
3A4
-targeted
lipoprotein
Also
altered
absorption
MMA
infusion
sex
twice
designed
CDA
LDL
1.1
Bcr-Abl
apparently
prevention
achieving
separation
DMA
mammary
C0
H
regulation
defects
regulated
RIP3
mitotic
dyes
information
SNPA
already
limit
Taxol
replaced
rs3213207
0.0003
mdr1a
side
max
maternal
FDA
stress
co-trimoxazole
bispectral
naloxone
From
activating
predictors
-like
medulla
Bax
c
anaplastic
34
reduce
CYP1A2
N-methyl
-sensitive
exposed
evaluation
TAC
c.428G>A
2D6
cytidine
telaprevir
rs6465084
specifically
absent
ATP-binding
Tat
Han
approach
protocol
h/mL/mg
UGT1A
aged
225
sucrose
2C19
being
Impact
MPA
isoforms
geometric
salmeterol
staining
CYP1B1
AML1
pyrophosphatase
headache
classes
Neither
Oral
cortical
rs776746
interleukin
-1438A/G
attenuate
D-aspartate
cytotoxic
blocking
.002
58:01
invasive
separate
heavy
ve
Activating
beneficial
RT
prescription
GST
final
maximum
AIM
myocardial
documented
prognosis
4.0
glycogen
TPH1
obtained
cutaneous
supported
log-transformed
polyps
alcoholic
Jun
activates
Q151M
terms
60.7
periods
8-OHdG
express
techniques
77
WFS1
M
approximately
0.034
overexpressing
LAM
0.007
objective
long-term
1.5
systemic
Warfarin
protection
Pak1
dramatic
Ins/Del
excellent
rifampicin
Potential
Val66Met
relevance
natural
blockade
precipitated
derived
RUNX1
leading
LL
markers
HT
0.004-0
suspected
epirubicin
c-Jun
inflammation
hazard
implying
Study
consumers
streptozotocin
CT
protect
MnSOD
opening
NADPH
efficiency
supplementation
hematologic
CDT
estimated
cluster
transferrin
measures
resulting
learning
defining
desensitization
tenofovir
H-ras
rapid
c-jun
Human
fibrosis
immune
C57BL/6
Long-term
treat
quantify
occurring
inorganic
prescribed
CHRNA4
underwent
biomarker
modifications
Specifically
additive
non-SVR
mutated
intestinal
mu-opioid
zidovudine
6-MP
src
fertility
VDR
carvedilol
TK
Gefitinib
Han-Chinese
aldehyde
indicative
ANKK1
alcoholics
applied
immunohistochemistry
explain
c.3435C>T
supplement
monoclonal
salbutamol
RY10-4
hormonal
availability
MC
Genomic
loading
folic
M1
C>T
eIF3a
certain
Parkinson's
borderline
Common
systematically
until
once
NQO1
Identification
partly
modulator
transporters
DOR-1
transformation
MATERIAL
components
progenitor
BCR-ABL
Conversely
MDRI
metastases
cerebral
myoclonus
Stevens-Johnson
extinction
X
endometrial
sequence
axial
exhibit
pivotal
GH
Studies
0.04
icotinib
increasing
larger
neu
high-
field
tryptophan
S-transferase
Similarly
conferring
signal
tobacco
_
conversion
block
supports
VCAM-1
life
creatinine
OCT2
.005
Indians
encodes
Phe
mellitus
complete
intervention
adequate
depression
elevation
stenting
S-warfarin
accounts
Polish
-containing
I3C
occur
now
MUT
rs2884737
AF4
rs12979860
SJW
CRC
Findings
demonstrating
potently
bleeding
comparable
DGF
Beta2
longer
diabetic
MCRC
C/C
BMD
progressive
second-line
-5
C282Y
c.1236C>T
transformed
EXPERIMENTAL
patterns
conclude
published
candidate
antiproliferative
Ile
alanine
fat
oncogenic
OPRK1
diagnosis
Age
nephrotoxicity
correlations
consecutively
T1
rejection
general
hepatocytes
SD
Th2
led
None
acquired
Cr(VI)
observations
predominantly
possibility
BSC
ENO2
signal-regulated
23
deficits
Evidence
artery
Catechol-O-methyltransferase
3C
POR
concurrent
explained
checkpoint
concluded
Kinase
overcomes
Carriers
discounted
oseltamivir
investigating
address
matrix
5-HT(3A
rs6265
6-BG
preventing
-TKIs
gadoxetic
implication
severity
endogenous
stem
describe
Accordingly
15
plants
consequence
slices
channels
intravenous
resulted
PCR
A2/A2
caspase-3
average
kappa
anaemia
antisense
MAO-A
consisting
METH
beta2-adrenergic
P-glycoprotein
RAF
segments
propofol
L90M
remained
bupropion
SSRI
e.g.
emission
spontaneous
Following
MDS
BEZ235
would
RRM1
pregnancy
immunogenicity
MDR2
AZD6244
S.
cortex
bioavailable
thyroid
stratified
probably
portion
homologous
aromatase
TD
water
still
NO
interest
Growth
analogs
rats
Drugs
retrospectively
BCR/ABL
chloramphenicol
identify
potentially
skeletal
mild
DAPT
dysferlin
needed
Hcy
TPN
females
BRCA
flecainide
glucuronide
sunitinib
scores
sterol
glial
immunosuppressive
tool
Molecular
highest
debrisoquine
T315I
mutation-positive
angiotensinogen
utility
density
sodium
vinorelbine
talinolol
A/G
AERD
cyclooxygenase
progression
-terminal
attributed
nelfinavir
sites
amino-acid
PACT
linked
microsomal
cognitive
V600K
GNB3
excretion
Finnish
DTNBP1
accounted
adjustment
sequenced
familial
MEK1
effusions
Acquired
inducing
restenosis
ALDH1A1
controlled
adrenal
Wt
Rhes
Another
weekly
abolishes
having
4-HNE
HSP90
times
Asian
families
MOH
dominant
kg
98
consolidation
neuronal
chromatin
order
PR
routine
Multiple
azacitidine
acetaminophen
eye
challenge
suppressor
-deficient
Influence
cultures
greatly
chromosome
0.1
CAT
Recent
ADH1C
efflux
functionally
analgesic
corr
1A1
compounds
300
-regulated
importance
amiodarone
CsA
sulfate
With
ADORA2A
production
trait
While
augmented
acetyltransferase
72
DHFR
catabolism
Regulation
decline
5-azacytidine
Dex
venous
NE
systematic
attributable
delay
personality
3435C>T
avoiding
leads
confirm
Cdx4
17-OH
non-drug
proliferator-activated
x
safe
microM
25
simple
pigmentosum
ventral
neurotrophic
mg/dL
repaglinide
consumption
CES1
adherent
inducible
application
antidepressants
S-mephenytoin
codons
Alcohol
anticoagulant
intensity
consequences
multikinase
Cmax
1A
atorvastatin
harbouring
abolished
vaccine
intracellular
fluorouracil
MM
dopaminergic
escalating
-1
(V600E
JAK3
Pcorr
XPD
treatment-naive
introduced
able
upon
677C-->T
delayed
substitutions
MSI
very
inhaled
DD
73
IMO
near
constructed
fluorescence
collies
-141
CQ
0.305
child
option
CXCL8
DISCUSSION
smokers
bortezomib
ESRD
antagonists
ethnic
critical
whole
malignant
insertion/deletion
prediction
anticancer
medication
0-infinity
contributes
IFN-alpha
dextromethorphan
polymerase
yield
P2Y12
subsequently
pravastatin
help
overload
midazolam
Dutch
high-dose
oxidase
Pharmacogenomics
reuptake
valproate
Src
GSK-3
monotherapy
attempts
cFos
APOE
combining
A2
HLA-G
NPHS2
Intracerebroventricular
2C9
heart
Sk-Ov-3
q21
tomography
animals
pronounced
Bcl-2
ivermectin
inferred
eNOS
man
psychological
aspects
17-AAG
characterized
-eGFP
Na(+)
metoprolol
TP53
HbA1c
cation
GO
acutely
young
equivalent
1502
cessation
independently
PDGFRA
rare
children
CD
glucokinase
DPD
Thai
a2-subunit
c-Met
levodopa
TNF-a
reversed
enhancer
multicenter
bile
therapies
1-(m-chlorophenyl)piperazine
null
hTERT
mTOR
Liver
mu
irreversible
GG
oxycodone
cytosolic
endocrine
accumbens
affinity
hippocampus
Tyrosine
subsequent
74
containing
screened
chloride
stroke
users
TCDD
indicates
amplification
BCL-2
Ser9Gly
ER/
cytarabine
systolic
despite
pleural
1D
D1
onset
TLR7
peroxisome
ALT
activator
pretreated
neo-adjuvant
T>C
oxidative
dose-adjusted
ARM
LFA-1
ADRs
met
relative
fraction
Many
ng
1.37
cigarette
Nav1.5
demethylase
EML4
concomitant
principal
t
CAR
makes
-selective
p16INK4a
replicated
CHRNA5
experiments
objectives
antioxidant
0.009
19
prasugrel
Combination
ventricular
caffeine
VHL
differ
slow
TT/CC
DRD3
dystrophin
Erlotinib
Both
RARa
prostaglandin
repeat
nucleoside
105
Single
fumigatus
influencing
various
H3
MLKL
rs7294
neither
rsGFP
repeated
taxane
Singapore
propranolol
incubated
African-American
06:02
tea
necessary
overuse
Indian
200
PTGS2
postoperatively
exacerbated
Pi
phenotypic
myeloma
escitalopram
cocktail
/day
confirmed
testosterone
protects
pregnane
frequently
mixed
afatinib
emtricitabine
ng/mL/mg
irradiation
08:01
nuclear
SERT
anticoagulation
seeking
shorter
cardiovascular
neuropathy
detect
neurotoxicity
positron
pridopidine
grade
xeroderma
Ser49Gly
p.Gly143Glu
Inhibition
anemia
goal
GABA
5-MTHF
dehydroepiandrosterone
NNK
CBZ-epoxide
basal
expressers
skipping
interacts
0.34
necrolysis
RAS
successfully
immunoreactive
Four
Currently
presented
glucocorticoid
dramatically
INH
delta
thickness
202475-60-3
deoxycytidine
47.6
cells/animal
inherited
muscarinic
check
hot
childhood-onset
421CC
older
hyperhomocysteinemia
stimulated
CaMKII
RDEA119
subtype-specific
b-adrenergic
survivin
peripheral
252
(V617F
considerable
paper
scans
CPP
down
57:01
domains
15-fold
c-abl
heat
b2-receptor
4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline
ineffective
NSHL
ABCB2
6-38
+24
subepithelial
Situations
acetaldehyde
GR
nigrostriatal
.2
rs1934951
rs1059288
dideoxynucleoside
cause
wt
Oxa
Y621L
ABO
flashes
unlikely
transcript
Recipients
V617F
.The
Purified
chi2
RGS2
MEASURES
regresses
multi-
LIPC
distinguished
APP/PS1
1.10
Further
55.2
cell-based
sulphone
VEGFR2
9-benzyl-8-hydroxy-2-(2-methoxyethoxy)adenine
.007
Similar
VEGFR3
rs307821
fall
Cyclosporine
FK506
beta-hydroxylase
Upfront
0.3331
human-2
rs448012
regimens
afforded
val66met
estrogens
conduct
impressive
acquire
248
sulfamoyl
structure
recommended
acting
0.001-0
Efficacy
D-serine
ensues
N-acetyltransferase
line-derived
evident
I399C>T
Comparison
DSS
Inter-individual
butyric
IPASS
significance
SN-38-glucuronide
pERK1/2
analogues
0.08
1V136
/ARE
Of
rs1045642
percent
drastically
truncated
why
remission
extreme
T_T
recombination
buspirone
.40
biosynthesis
competence
catecholamine
extra
PNA-AAV6
JUN
explanation
pills
Lyon
obese
ht1
program
PEW
haemolytic
concentration/weight-adjusted
poisoning
biomarkers
mostly
0.35
MEK1(E203K
FOS
few
SULT1A3
ATP
CUDC-101
far
asked
MPH
40.7
BMI
rs1126647
KROX-24
GCKR
ages
UGT1A7
MT1-MMP
adding
high-risk
600-mg
779A/C
DMXAA
Hanover
sulfating
LoVo
pre-treatment
rs1799809
ritodrine
compound
ADH
feasible
5,10-methylene-tetrahydrofolate
3A5
AIAU
FR-pQBI25
GABAA
3.5
gene-1
valspodar
Adenosine
8-oxoGua
GIRK2
833
fluoropyrimidines
instability
MGP
GABRG1
19.95
Amazonian
undertreated
syndromes
mixture
makers
keratinocyte
summary
except
transmission
ST
Levels
subscale
XBP1
Intriguingly
ibudilast
phases
members
Q56P
protocols
late-stage
matrine
G143E
Scale
Combinational
metastasis-free
I/II
anaplerotic
GLUT2
translate
ERK1
Bucindolol
proglucagon
2.24
IL-1B
flux-based
phosphatase
busulfan
AT1R
rs35597368
bulk
pertinence
multivariate
Ile160Thr
D3
appearance
theories
oxygenase-1
success
polypeptide
canine
TNFalpha
1alpha,25-dihydroxyvitamin
ring
magnesium
last
CL4
cascade
hMOR
NZW
Sensitization
Malaysian
BO-653
placement
melanomas
newborn
Few
OATP
co-mutation
symptomatology
SNRI/
questionnaire
1.005
B-Cd
alpha4beta2
clotrimazole
accompanied
irinorecan
synergistically
debrizoquine
Hydralazine
resequenced
35
p-values
Na
optimise
699G>A
ART
DEX
MT1A
leptin
stimuli
pmol/min/mg
:10.1038
PKAI
-38
A-alleles
0-12
reserve
polyphenols
vaccination
p-value
calcium-sensing
overanticoagulation
four-drug
chain
-internal
guarantee
RASSF1A
Drd1
stratification
cyclosporin
MSNs
mechanistic
evidenced
confirms
NAc
chance
DNAs
evoked
signalling
pooled
discuss
delays
Management
311
budesonide
-prevalent
hOGG1
N265M
commercially-available
excision
violence
incorporated
abusers
adolescents
fusion
gene-environment
I141M
phenobarbital
0.430
dismutase
N-acetyl
2E1
0.836
HC/LF
IMPase
effector
polyphosphate-1-phosphatase
SCD
mitochondria
recognized
interfering
peripherally
platelets
albumin
follow
limitations
coagulation
XIII
L/L
probable
f
Monitoring
0.031
/injury
und
transforming
aflatoxin
Val34Leu
G172T
INTRODUCTION
toxin
potentiation
module
etoposide
explored
post-operative
-.234
folinic
profoundly
MPAG
topography
Cumulatively
NZB
crucial
rate-limiting
great
cholinesterase
germline
temsirolimus
PAH
biochemical
tagging
R408W
initiation
transfusion
EMs
performing
co-morbidity
living-donor
SCFAs
DAT1
malignancies
thrombotic
gatekeeper
acitretin
bAt
SRs
aggregation
Asn680Ser
eriocalyxin
thioguanine
adipose
drink
atenolol
1.46
lambda-3
.24
8.46
-reactive
drug-resistance
rs165599
siRNA
utilization
covariates
Trial
SKOV-3
multiple-dose
oligonucleotides
removed
single-centre
establish
15-keto-PGE2
cysteines
enterocyte
OATP1B3
1.08-2
analogue
Arg389Gly
descending
opiate
phenotypically
rather
IgG1
nalbuphine
Cytochrome
hetero-monocyclic
NR1I1
contained
PDA
WCA
25-OH
derivatives
chromosomic
CCA
knock-out
BAG-1
endotoxin-associated
colonic
-R
Tenofovir
knock-down
Jo2
multicentre
cytogenetic
Ala189Val
339-345
Saururus
genome-wide
l
Nicotine
consented
Akt
sexual
expressors
Month
C0/D
PlateletWorks
APOC3
m
Wogonin
existence
non-interferon
tablets
Pharmacokinetic
G0103
BECN1
normalized
non-synonymous
.006
risks
DSF
raltitrexed
anastrozole
reactivation
.1
TaqIB
3.73
16Gln27Thr164
420
1826
-1.4
/EBPb
Presence
titers
moderated
event-free
resting
G565A
Novartis
15-PGDH
networks
triphosphatase
6G-->T
Gastric
maintained
Variability
Pharmaceuticals
na
APL
677
Huntington's
changed
Ab
done
2.31
prostaglandins
2B6
amyloid
Compared
psychiatric
GP
dorsalraphe
focus
AhR
azole
situ
JANEX-1
B-cell
Before
TIMP-2
.049
28B
developing
(CYP)
HLSZ
521
topiramate
beta1
2.91
dose-normalized
NVALT
polyneuropathy
3-week
264.7
wild-types
tapering
ABCC1
Male-specific
-AT1
ACS
Diplotypes
Taq
IGF-1
radiosensitization
Kirsten
OGG1
pulmonary
0.19-1
knockdown
GIST
340
shRNA
V71I
POPular
lenalidomide
VKORC
localization
rs622342
-initiating
viral-mediated
repeats
injected
Preventive
E(2)
.57
1.4-fold
ARE1
ApaI
stasis
Arg389
late-onset
-1.0
fetuin-A
surrogate
Normalized
duodenal
prostatic
4-aminopyridine
assessment
33
fluorofentanyl
HSD17B5
C-65
Peg-rIFNa-2a
Icotinib
relapse-free
18
analyze
moderate
letrozole
mdr1
-Adrenergic
signature
CRHR1
0.5
element
airway
Fms-like
Lansoprazole
5-HTR2A
SLC6A12
0.534
SCF
5-HT3
472,200
monocytes
Inhibiting
disappearance
Two
Female
M41L
medulloblastoma
cilengitide
preprodynorphin
BC
islet
Possible
heritable
47-year-old
rs35349697
Homer1
LSZS
confocal
rs737865
CBZ-diol
i.p.-primed
cycling
likelihood
HMG
highlight
anxiolytic
mL/min
circadian
48h
addicts
robust
CCT5
primate
rs4925
SRE-1
Five
.0001
immunomer
myelodysplastic
black
90
parasites
mithramycin
cysteamine
gastroesophageal
-haplodeficient
86
French
376
immunodeficiency
monitoring
3A
polycythemia
thienopyridines
0054
dasatinib
SQSTM1
860
Analysing
expiratory
S/S
wildtype
44
Pompe
0.45
androstenedione
1.34-150
alkylating
v-raf
CYP450
genetically-determined
progestin
1.01
hydroxyurea
firstly
outpatient
TO
Expression
cardiomyopathy
.023
PU.1
1954
design
monophosphate
antibodies
endemic
Raf
recall
Bupropion
MMA(V)
Examining
gammaH2AX
12-year-old
CTx
ERalpha
10.2
lipids
quantitative
eradication
testicular
Asp(9)Asn
exon-skipping
CIMP-positive
genetic-potentiated
IU/L
neoadjunctively
research
rs1076562
point-mutated
tolerable
dogma
247
permutation
curcumin
TPO
Abacavir
-hypersensitive
substitute
Norepinephrine
-deficiency
olaparib
distinguish
metabolize
regarded
Heterozygous
antimode
/5-Fu
Proguanil
parameter
cuff
glycosylation
Gly16Gln27Thr164
NRXN3
future
fracture
(S)-3,5-dihydroxyphenylglycine
Taiwanese
Smad2
Bt2
GFP
rs11085735
needs
resonance
R/R
methiodide
restricted
mortality
TKI-na
smaller
SN-38
sertraline
altering
All
too
transporting
equilibrative
offered
-embedded
184
traditional
Th1
external-beam
recurrences
1.5-fold
4.33
78
RO4987655
helped
excitingly
Knockout
Prevention
Targeting
delta-aminolevulinic
characterize
specification
rs9479757
validation
novo
carnitine
IOR/OS-1
hypertension
differential
IM3829
ethnicities
2.371
Cho
milbemycin
subjective
saline
9-month
product
T286A
participants
Smad3
CPT
Hydrochlorothiazide
P1655
Niemann-Pick
EC
PSC
albeit
Aspergillus
empty
Ser10Ser
dorsolateral
cooperate
examining
CES
three-locus
locomotor
drive
.0002
y
EFV
Given
PC-BSA
-1175
diffuse
features
double-strand
90-fold
0.005
MspI
LPS
rs886003
plasmatic
short
exploratory
haemoglobin
CNI-
microscopy
deletions
IMs
engineered
0.003
177
DDP
.74
-485C>T
500
Inventory-II
habits
A1
-immunoreactive
gene-promoter
104
UDP-glucoronosyltransferase
Met233Ile
0-6
underlying
Conditional
0.94-1
+8.6
They
apply
executive
percentage
G010401
CDK1
Arg555Trp
co-administration
Kainic
6.2
lipoprotein-
p450
Several
Screening
curative
389Gly
FEV
Adjusted
logistic
comparisons
naringenin
discontinuation
CRH
3.25
verapamil
Associations
Infection
47
14.18
816
PARP
transcription-3
above
dystrophy
17-Hydroxysteroid
IL18
radioactive
diagnosed
Ainu-selected
addicted
probability
releasing
appropriate
MAIN
intron
-had
lethally
polyphenolics
small-molecule
BCR
A.
IPA
mitotoxic
spinosad
UDP-glucuronosyltransferase
irradiated
18B
46
unfavorable
subclone
MOR-1
Evaluation
-responsive
adiponectin
deferoxamine
preferred
rGH
contribution
20.0
25.1
Sv
0.010
intragastric
acarbose
5-
Aspiration
IHC
hepcidin
rs1695
GSTO1
CHD
establishment
neurotransmitter
PVN
elucidate
0.063
HRAS
rs156697
activate
symptomatic
usual
OUTCOME
switch
H1-antihistamine
bladder
hybridization
immunized
PKA
phosphorus
residues
condition
estrone
IgG2a
GSTA1
atypia
mutation-negative
Modelling
quality-adjusted
linkage
RU-24969
deficit
His
radiosensitize
person
anteroventral
Triallelic
mainly
Withdrawal-induced
saquinavir
C3
CES2
mid-digital
sarcomatoid
dysfunction
1.6-fold
ultrarapid
HCV-1
q22
-transferase-omega
favourable
pulmonologists
monogenic
predicted
protease
ERN1
withstand
monomethylarsonous
sensitizes
WHI-P131
mefloquine
characteristic
urine
metastasis
MATERIALS
hamsters
Asians
210
reasonable
0.60
protruded
1.11
vulnerability
PON1
Southeast
domain-containing
PP(i)
initiated
naturally
contributions
Scr
CDDP
Regarding
Analysis
Iressa
substantially
cefadroxil
-wildtypes
apomorphine
enrollment
hydrolytic
pathological
Asp299Gly
methylphenidate
intact
Lipoprotein
3.8
Homozygosity
Fourteen
cost
carotid
consumes
/C
African-specific
NAD(P)H
polyphenolic
antioxidants
WNT
-agonists
MAO-B
rs9263726
13-diacetate
earlier
LS
1.22-6
retrospective
modulating
6.5
randomised
LDLT
yohimbine
p.I359L
enters
network
relapsed
component
white
222
measurable
Y1
Val30Met
GTPase
0.393
288
metabolisers
39
intercalated
SCARB1
FISH
129SvEv
prolongs
180.1
vasospasm
Cocaine
transiently
Metoprolol
IVS4+76G>A
IVS12-5676A>G
22
rash
LDF
tolerability
nephrotic
deep
comprising
encephalopathy
SSRIs
breakpoint
ADP
-activating
mmol/L
cautiously
perception
5-oxime
E-cadherin
PDGF-R
lineage
Functional
mitomycin
biopsies
bilayers
rs4653436
planar
VX-770
CHOP
Consequently
prescribing
neural
epigallocatechin-gallate
Ile105Val
DT-diaphorase
RAD51
ameliorate
hypothesize
usefulness
modifying
inductive
reach
(HLA)-B
-2005
LTD
STMN1
lithospermate
Egfr
Jordanians
Twenty-seven
.95
-mutations
remains
MT
low-fat
resection
elective
vehicle-treated
Patient
ALAD
individualised
-3.31
time-related
oxypurinol
MMR
T-
wall
haplotype-dependent
EPT
contains
backcrossings
non-selective
Gly16Glu27Thr164
mercury
MC1R
process
GCTATA
prefrontal
vinblastine
CH4987655
hypersomnia
rs671
expansion
dehydratase
CG
A156V
A1/A2
pramipexole
2C
Donors
MAbs
demonstrates
personalized
high-level
PMH
pretetanic
preoperatively
analogous
0.016
polyphenol
CL
6-hydroxydopamine
SCNN1A
seizures
G15631T
Kv1.5
Leukaemia
C>G
stomach
prophylactic
KCNA5
Journal
VerifyNow
Genome-based
converting
PC-3
Colorectal
516TT
synaptic
haploinsufficiency
IFNL3
POG1
abstinent
M253T
Gly16Arg
definitive
CD80
Apoptosis-related
implicit
Thalidomide
F508del
somatostatin
ICER
HLA-G010403
suppressed
synergism
PEI
raclopride
correction
STAT3
ErbB-4
location
c-Kit
1.61
transfer
LTA
allografts
HTRA1
A/A
FINDINGS
O6-benzylguanine
automatically
HER-2
2006
stimulation
SN-38G
-LI
1.14-2
boost
CRAd
ErbB-2
Cycloheximide
C-MYC
EIACs
First
A1298C
leucocyte
AWS
non-intoxications
elevate
CCKBR
dose-corrected
rs2228576
co-segregate
hsCRP
TTR
flushing
Drug
Associated
codon751
PDAC
Asthma
NK
ENPP1
147
excluding
HapC
TRb
2013
dimethyl
inconsistencies
5-FC
leucine
Abl
geographic
GSTs
HT-29
Tac-QD
Mediterranean
pre-selected
rs1799884
Toll-like
antagonistic
-30G>A
-Induced
analgesia
Kuwaiti
governed
remarkably
APOA5
gonadotropin
presentation
example
-evoked
affective
p-
p25
Recently
157
cytogenetics
YAC-1
assessing
-Mutant
cold
T-lymphocytes
IL36RN
positively
HTPR
marrow
MVA
okadaic
Kyushu
HDAC6
computer-assisted
0.002
centrally
TCF1
V118I
accumbal
-1.3
single-stage
efficient
adenoma
inhalation
Env
respiratory
Chronic
copper
TULIP
NH2
closed
HER-2/neu
Fgl1
respiration
PGR
bCD
necrosis
PD-0332991
R406
CTX
intraindividual
I/R
pneumoniae
luminal
ACTH
manipulation
.62
virtually
DPYSL2
montelukast
tricyclic
DCK
unchanged
autonomic
Cu/ZnSOD
227.8
catalytic
2.64-fold
Wy-14643
HSS
replication
occasional
tine
non-hematologic
disadvantaged
-514
well-being
naltrexone
23S
K562/A02
putative
correlating
3-11-fold
-H
head
TRAIL
idarubicin
islands
phosphodiesterase
141
GABABR1
glomerulosclerosis
simultaneously
vincristine
5-fluorouracil-5-FUDR
sarcoma
homeostasis
muscular
Preliminary
abrogates
0.314
worldwide
brushing
desensitizes
elicit
social
metabolically
Viruses
5-aza-2'-deoxycytidine
(IL)-28B
macrocytosis
SN
208
highlights
CXCR4
1494C>
all-trans
CYP2A8
D2
diol
corticotropin
AKR-501
11C
MBP
abrogated
codes
H63D
Younger
lopinavir
lineages
Protective
mg/kg/h
untreated
nervous
responsiveness
PCOS
Ecstasy
Lymphoma
facilitated
witnessed
371.9
determination
CA
IL8
41
82
Thr449Ile
ERCC5
statin
silencing
degrades
translated
66
stavudine
Trastuzumab
intake
dose-response
Program
324
-835
PRIMA-1
hyperabsorption
Caspase-3
DSG
strains
C77G
p16
profound
-Microglobulinuria
July
-3.04
ALT1
adhesion
sputum
yang
neocortical
conjugated
SLCO1B3
rs9606186
alelle
variabilities
T790M
5FU
ng/mL
extrusion
woman
transducer
sufficient
5-HT4
emphasizing
power
IPPase
unaffected
L.
mutagenic
Random
5-(arenethynyl)
0.93-1
source
Simultaneously
post
-455G/A
U0126
absolute
prevailing
relatively
post-PCI
VRX-480773
differentiating
kinase-9
NCT00352014
revolutionized
viremia
GABRE
Ser358
1.05
observation
7.5
responds
hyperacetylation
fluvastatin
phorbol
reverses
clearly
Childhood
renin-angiotensin
intertwined
accuracy
hypothyroid
rs4795893
mAb
0.20
deficient
ortholog
insight
methoxsalen
liver-specific
Paraffin
3.517
/T
+25
Nexavar
1075A/C
F2
biopsy
m-CPP
SLC19A1
Altogether
10.4
Seven
hypoglycaemic
F624
MDA-MB-231
Green
rs3745274
anthracyclines
procured
miR-122
embryonic
cance
2.2
ERK
forced
causes
oridonin
Fine
solution
taste
achieved
beta3
exons
II-
DM1
ipsilaterally
-pretreated
o
NRTIs
Fifty-two
peg-interferon
HN31
BPRS
Native
triheptanoin
c-erbB-2
hyperplasia
ligand-independent
FRA
-LPR
regulator
NOS2A
D123G
(-)-epigallocatechin-3-gallate
pharmacoepigenetic
FKBP4
N/S
caspase3
valuable
0.054
http://clinicalTrials.gov/
Dose
His611Arg
generalize
retinoid
beta1-AR
K562
36
p.Asp260fs
define
meta-analytic
rs4149013
HoxB4
facets
COX2
bcr1
rearranged
hypoxanthine
fexofenadine
real-world
5.00
p.Glu545Lys
VEGF-A
tranylcypromine
-399A
MnCl(2)
nonsignificant
fewer
acts
min
0.369
raltegravir
Proenkephalin
11.4
H4
rs1360780
HEL
HPLC
motor
N-methyl-D-aspartate
-linked
RATIONALE
rs1570360
rs2619538
Logistic
00
UGT2B15
thrombocytopenia
anti-inflammatory
e
Tac
inter-individual
CETP
inactivation
amodiaquine
F617
0.603
units
rs1042714
Consortium
MIA2
59
T939C
Modulation
apnoea
oxides
maculopapular
175
A1/A1
seven
pombe
rs29230
allele-restricted
morphological
BRCA-2
BAFs
hair
humanized
types
Roscovitine
single-arm
182
ABCC10
nominally
evolution
Carbohydrate
discussed
ytogenetic
opposing
Phenotypic
FOLFOX
GABAB
Periareolar
synonymous
participates
UGT
involving
besides
T102C
NNRTI
aurora
Irreversible
FokI
copolymers
stiffness
RAW
Thal
PTC
PASMC
concentration/dose
RAS-
1173T/C
Arg399Gln
prednisone
Genotyping
Y181I
histological
dopa
fatalities
mizoribine
internal
GACI
Cr
glycosylated
Transforming
holds
counterparts
disequilibrium
CD86
quinapril
direction
Therapeutic
GCV
42
0.084
1.4
enrolment
placental
MCJ
SNPSpD
chronically
multi-drug
manganese
Hippel-Lindau
Conjugation
G/A
GSTO2
retinoic
sibutramine
11q
prothrombotic
norclozapine
prostratin
stress-induced
Bag-1
behaviors
ras
SDS
range
phosphorylcholine
spindle
tolerated
AC
intensive
1.89
97
responding
vasodilation
engraftment
nonphosphorylated
SkM1
Inhibits
concentration-dependent
YKT6
fibroblasts
silibinin
rs1051266
29
bearing
potency
MAOA
progesterone
arcuate
venlafaxine
sex-linked
rs2740574
chronopharmacokinetics
2.53
North
Luciferase
implicated
Need
mt-
CML
suxamethonium
C-sweat
56
2011
SYK
LTP
LDH
heterogeneity
Taxotere
HCH
+14.3
GSTpi
Canadian
CFH
selumetinib
Insulin
down-regulated
rs5376
considerations
0017
Gly389Gly
green
HLA
Capecitabine
250G/A
5'-hydroxy
PML
Thr260Arg
best
prednisolone
finger
T1974C
GATA4
low-activity
MFG-E8
clonidine
NPY1R
SM360320
hENT1
pindolol
PCT
G0105N
presently
3.07-65
elevates
Analogously
Inhibitors
minutes
extends
course
Differences
12.57
AZD1152
tpj
Nebivolol
sinthase
vera
western
periventricular
Immunohistochemical
.5
corrected
CYP7A1
Identifies
cryptotanshinone
ELK1
uterus
frequent
mitogen-activated
laevis
amygdala
Gilotrif
anti-HBe
IFNa-2
elderly
tegaserod
element-1
Serotonin
codon23
mitosis
sulfhydryl
quetiapine
indicators
Inventory
F617L
TAPBP
RESISTANCE
aberrant
phosphatidylinositol
C1236T
reabsorption
L/S
soyabean
381.6
0.709
isogenic
cycles
Pooled
prodynorphin
Taking
ADIPOQ
circulation
TGF-beta
unique
decisive
nanoparticles
87.5
IkappaBalpha
rs17862325
-1.6
A-241G
haplotypic
oxidation
apoptotic
fear
GST-P1
beta2-AR
Oncology
0.508
cooperates
alpha-thalassaemic
comorbidities
INRs
rs12714145
lymphoblastic
anticonvulsants
encode
ranging
effectively
downregulation
routes
C-to-T
521TT
predispose
transport
codon
Australasian
Du145
Jews
AOX1
hemizygous
aldosterone
cyclophosphamid
.03
71
remarkable
STZ
hence
antioxidative
rs121912777
-3435CC
taxanes
antiepileptic
2.95
nano-imaging
homologue
starting
face
bipolar
promotes
medial
hypersensitive
Withdrawal
MAF
agonists
produces
warrants
currents
cycle
isolated
mdx
0101
CB1-R
practice
enzyme-inducing
.90
multi-kinase
S107
schizophreniform
measuring
equally
Doses
chemokine
underanticoagulation
schizophrenic
MARCKS
transient
Pak
HCC-1937
conditional
c.421C>A
rectal
c-kit
rs6943555
CAN
dibutyryl
DIO2
kb
CCR3
D314A
DdeI
mono
enterocytes
NFATc4
Xenopus
Asn(453)Ser
CRT
-.212
crisis
PTEN
infants
-acetyltransferase
substance
strain
ABL
almost
co-administered
Receptor
promote
dl-PFC
a-2
proteasome
orally-active
FcyRIIIa
pertuzumab
ADAL
doxifluridine
decrement
pSTAT5
controversial
colitis
threshold
ameliorates
malondialdehyde
30.93
interferon-alpha
F227L
Maprotiline
CF
18years
PI3K
80
cervical
HepG2
rs3957357
PCI
POMC
procarcinogens
PI(4,5)P2
enrichment
reliably
G12D
possession
1.52
Current
0.028
hypotheses
HCC
endothelium
carbohydrate
521TC
trough
traits
fibroblast
S326C
6.0
intestine
Mutated
Twenty-four
PET
Thiopurines
unfavourable
Factor
Instead
intolerance
HAGE
-for
etiology
isoniazid
53
zif/268
1069
mg/kg/d
1173
Overcoming
15-pS
demethylation
+17.1
42.9
kainic
limits
GUT-70
crystal
littermates
bilaterally
acetylation
GENDEP
MBC
P26R
haplotype-specific
sweat
Acetaminophen
hepatocyte
Itraconazole
mug
International
contraceptive
TG/TC
E+P
up-regulating
hypoxia
0.018
L4-L6
controlling
carisoprodol
88
conducted
antagonism
ITF2357
motives
intramuscular
peroxide
contributing
guide
definite
problems
template
PVP
solvents
G-Rg1
.0005
FKBP5
A1166C
candidates
PDD
feature
experiences
Recurrence
chinensis
creatine
S-1
significiantly
GRIN2A
JBCRN
CTL
BRCA2
TYMP
94
22,
glioma
235T
mg/day
M204V
7.3
phosphatidylcholine
interferon-free
p.Glu542Lys
Rare
transaminase
CMI
omega1
-all
alpha-globin
NRAS
immunocompromised
1639G/A
0.12
Enzyme
Cyp3a5
reliable
Veliparib
propionate
Whereas
random-effects
ARRY-142866
ChD1
phenacetin
Tri-Phosphate
blockage
N-terminal
Detection
JTC801
Toxic
Merieux
antigenicity
subnuclei
myocyte
prevent
R296C
MDMA
AMD
0.82
advance
alteration
ACHN
0425
donor
0.628
close
0.88
homozygosity
immediately
279
forkhead-associated
hippocampus-dependent
Pdyn
421
microsatellite
LXR
4-OH-TAM
expectancy
Asn334Ser
thought
karyotype
similarly
view
Newly
proteinuria
damages
IUI
suitable
DFS
myocytes
emilin/multimerin
Institut
45
rs1128503
Discovery
CD55
costimulatory
Importantly
drinks
Gene
5-lipoxygenase
ASMko
PC
reasons
swelling
nitrosamine
paraventricular
-Related
exerts
Single-nucleotide
-1.2
La/g
well-characterized
upfront
RB1
involve
misfolding
remaining
food
transmittance
C.
rs4952
relationships
score
ABCA1
caspase-8
mediate
augmentation
trametinib
often
toxicities
Ranbp2
additionally
quinazoline
high-activity
FLG
triiodothyronine
females-despite
G48V
base
Cln
interleukin-3
BRCA-1
slight
MAPK
abated
regard
AZD9291
stages
catabolic
0001
care
cooperatively
regarding
driver
Y414C
-45C>T
D2-like
reversible
variables
That
Successful
H-2
AMP
tetrodotoxin
CAS
temperament
5843-6276
acquisition
eliminate
GCK
1C
NTS
mitogen
cysteine
rs2231142
AGT
polluted
positive/
gender-matched
A218C
SR
regulating
reflect
aminotransferase
Prediction
Ala-->Val
Interactions
Higher
CASE
routinely
Ezetimibe
fasting
Pregnancy
840-mg
biotherapy
abundance
problematic
consequently
N-oleoylethanolamine
HTR1B
Y621
zygotes
dysregulation
synthesis
across
Fe
Despite
As
Folate
commissural
.22
cobimetinib
ABCC4
0.017
FAS
blotting
Angptl3
4'-hydroxylation
Bcl-X(L)
CDCA
Phenytoin
STAT
thalidomide
CRF
booster
Intercellular
CYP19
Nyholt
g.-1639G-->A
Dabrafenib
rs1870377
AVT
2016
assays
vegetable
TaqIA
pharmacogenomics
FTND
1.31-4
mimics
/S/A
leukemias
VPA
arsenate
third
GNAO1
Afatinib
1.47-3
taking
alfa
-118
-possibly
Considering
strongest
Pharmacogenetic
5.2
anthropometrics
mg/kg/2
self-infusion
mineral
Genomewide
pro-drug
ARMS2
hematological
physiological
2677G>T
estrone-3-sulfate
1976C>T
interventions
Vimentin
Confirmation
transcripts
domain-like
addictive
exact
desipramine
leukaemia
overexpressed
aims
up-regulation
tissue-binding
ablation
non-expressors
tBHQ
40-50
Women
1,647
core
CSNK1E
instrument
entities
ceramide
rs2071888
itself
3-hydroxy-3-methylglutaryl-coenzyme
neck
detrimental
favor
s/s-allele
contributory
generations
alpha-hydroxylation
Ala-
confounders
non-expressers
aetiological
Crizotinib
modification
reinvestigated
c.2846A>T
neuropathic
chose
recipient
rs2305948
shortened
muraglitazar
-to
copolymer
0.511
C1-Like
retina
P446L
ECOG
region-Abelson
intrinsic
intoxication
16.23
0.023
cohorts
Selectively
HLA-DR
Functionalized
CHC-I
Celecoxib
chemoprevention
native
speculated
species
ER-alpha
C3-C6
rs13273672
narrow
GST-M1
CD34
RE-challenge
I50V
interference
PAHs
epicutaneous
/SHOP
Participants
aggregometry
alpha4
hemodialysis
end
replacement
capsaicin
rs13273442
knockouts
(-)-epigallocatechin
copy
testis
plasmids
ILD
rs699664
publication
helpful
Experimental
AML
Because
5-fluorocytosine
complexed
5-HT(2C
sumatriptan
repression
GP2
SRNS
Rat
projected
c.2677G>T/A
ligand-binding
quaternary
disrupted
reinstating
N86/184F/D1246
3.182
-158
rs2115819
0.16
Multivariate
laboratories
presents
supraventricular
neutropenia
/low-fat
become
low-density
PPARa
pCR
cues
GC
rs16147
SFRS3
liposomes
playing
87
ribonucleotide
mGluR
HTR3A
pathogenic
Small-molecule
MRP1
86Y/Y184/1246Y
Ile(462)Val
pLXRN-4SRE-fPA
measurements
Solute
difficulties
Egyptian
LOGIK1004A
mineralocorticoid
endometrium
TGF-b1
1.101
0.0007
lumefantrine
Hsp90
AKT
exemestane
multinational
ChF1
Mutational
keratin
de
amifostine
pathology
120
Neuropeptide
mephenytoin
nNOS
quinpirole
Microsomal
alosetron
Ton.B210
enantiomer
alpha2C-AR
adriamycin
According
multifactorial
HPMA
anion
IFN-a
HMGCR
variance
international
AGXT
inducibly
stenosis
BEAS-2B
consistently
angiography
arrays
P-450
NFkB
causing
self-reported
impairment
SGCE
Type
MATE1
drinkers
pylori
Dukes
over-represented
experimentation
Needle
Roles
218
HLA-DQ
adolescent
rs699947
1.7
clarithromycin
AF9
BTK
conditioning
Ibruitinib
lenalidamide
anti-angiogenesis
H.
approval
translocations
rRNA
antiestrogenic
VH1
surgical
A2143G
PHSF
crystallography
prostaglandin-endoperoxide
age-adjusted
rely
nephrogenous
APC
1-34
samples
c.521
T674I
glioblastoma
1,25-(OH)2D
bioactivated
IL-18
INTERVENTIONS
Codeine
weight-adjusted
brazilin
V
inside
ROS1
neurobiological
7.19
illustrate
ip
g.15582C>T
fragment
over
0.006
AIDS
optimal
PDGFR
semiquantitative
SBP
platinums
Russian
namely
TM5
A-607C
retinol
NAD+
Gln504Lys
35-kDa
coenzyme
profiled
discovered
ARRY-142886
Selumetinib
w10
po
16.6
Negative
4.7
sappan
Arg389Arg
ear
poisoned
gene-expressed
-orotate
spermatozoa
Non-Small
artificial
postulated
CRBP
binds
gingival
judged
fluorescent
SLC22A2
Turkish
immunostaining
dichotomized
.01
breaks
80G>A
NIH3T3
specificities
1,3-butadiene
MMP
allozymes
blast
2-fold
unilateral
biological
400-mg
theaflavin
AIA
gamma
2'-O-galloylhyperin
Gln27Glu
Single-Nucleotide
ease
Pro12Ala
another
200-mg
-2.73
T-T-T-T-G
GAA
sirtinol
phosphate
PEG-IFN-alpha-2a
.001
adenomas
(V600
NR2B
1B1
removal
ALDH-2/2
management
12,
lovastatin
T181A
p50
kinetic
StAR
rs4680
FCER2
promotor
II/III
1p/19q
temozolomide
planned
entacapone
eukaryotic
Determination
in-depth
SSG
-IFN
focusing
many
understand
oPRL
retain
ex
up
Nutlin-3
0.368
-765G>C
poor-risk
launched
MDM2
nongenotoxic
piece
Q172H
WT1
plasticity
-amplified
b-blocker
4a-
UGT1A6
-1557
temperature
cooperative
Leukemia
HU
Rac1
CLL
detoxification
conclusions
foundation
--
Momordica
adjacent
TTX
gourd
EA
bitter
Crohn's
hyperglycemia
brachytherapy
ChS1
advances
degradation
sulphamethazine
5-aminosalicylate
suppressive
KU19-20
newer
lifetime
del322-325
thiazolidinediones
generation
glucosidase
context
PK
HL
oriental
technological
intima-media
CCl4
001
CD40L
inferior
methadone
forensic
autopsy
CC-IMT
PTCA
SrCl2
localized
irrespective
dose-dependently
p-aminobenzoic
1.27-2
adenocarcinomas
Gly389Arg
Elucidation
4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-D]-pyrimidine-2-(1H)-one
YM-64227
subtype
4b-hydroxycholesterol
Val125Ile
delivered
gain-of-function
HTR2A
undergone
optimized
xenograft
converts
3.6
3.55
thromboembolic
-ARE-
personalizing
HSFs
PD98059
Pharmacokinetics
(+)
cost-effectiveness
UGT2B7
workers
cigarettes
lobe
Posaconazole
immunoprecipitation
GSH
KIF3A
AUY922
peroxidation
aspergillosis
.2016.51
0.3
Rh
OSCC
tale
BalI
biotransformation
roles
Yin
CEL
thyroxine
flutamide
bicalutamide
N-cadherin
GIRK1
rs1042713
benefits
indinavir
Statin
AZD4619
catalase
living
mediates
SE
S-methyl
FMR1
unnecessary
Total
SS
Ectopic
ETO
RTQ
purine
suppressing
CN-AML
intermittent
Brain
question
-intolerant
partner
single-agent
insights
measure
subtypes
sympatholytic
glucose-6-phosphate
immunomodulation
indices
pazopanib
defined
two-fold
SU11274
rs1799853
Bruton's
NGFI-B
rs1260326
mol/l
chosen
T0901317
epilepsy
5-HT3AB
E
PLDIM5
0.494
WM
Kidney
Concentrations
Interestingly
G80A
/A
S-27609
LDL-lowering
181T
tanshinone
pediatric
167
17beta-estradiol
rs4646437
Models
MPE
knocking
mutagenicity
exanthema
-PDGFRalpha
IL-10
psychotic
rs2032582
(S)-mephenytoin
Bisacurone
.35
2/3
superior
IL-28B
catalysis
V600
genotypic
Sulfotransferase
hydroxyapatite
bath
1.11-1
segmental
supersensitive
S65C
focal
Q61
heme
XDH
nortriptyline
circulating
0.025
Tibetan
socio-economically
cross-resistance
liability
CYP3A7
TCPOBOP
name
TAM
A181V/T
N236T
Reinfecting
diazoxon
lymphocytes
158/108
terbutaline
DBH
NPM1
describes
rituximab
circulatory
Overexpression
isoflavone
Ratio
lycopene
histocompatibility
good
XRE
786-O
rs1800871
cleaved
BICD1
simply
exacerbate
environmental
red
14.1
oxygenation
AZD7762
FBAT
huntingtin
rs689466
apolipoprotein
TDF
GT
shed
Brazilian
GDNF
H3K4me2
0.041
follicular
secretory
ATRA
Transplantation
fluid
AZ
worthwhile
Finally
unconjugated
apart
rtA
Beck
mg/kg/day
0.0001
5.9-19
-0.31
BCSS
0.07
-0.54
SCAR
Onartuzumab
triazolam
intrathecal
Combining
Cell
within-gene
regressions
3TC
Arg-->Gln
ChU1
xenobiotics
Trabectedin
UGT1A8
abortion
2/14
pyrophosphate
HH
modified
Research
ethinyl
ISG/
calcineurin
subgroups
UTR
mothers
invasion
URE
predisposition
Bryostatin-1
modestly
catalyzes
coumarin
APPswe
PSEN1dE985Dbo
potentiates
surprising
reflecting
methylene
France
comprehensive
2.9
N-desethylaminodiaquine
rs2010963
AQ
nine
spatial
CoA
CEA
repair
galanin
conjugates
captopril
Bk2r
HCN1
10.8
LPV
currently
RTV
NODAT
0.217
diplotypes
offset
diverse
Development
superoxide
epitope
Nigrostriatal
8-week
KCNJ11
Positive
Syndrome
CCL2
period
BCRP
transports
structurally
demographic
actively
FDA-approved
impulsivity
stimulator
throughout
rs2857657
front-line
provocation
FOLFIRI
s
0.0004-0
volume
distributed
Cholestyramine
sitosterolemia
rs1024611
rs4586
diallyl
von
ABCG5
/8
Mozambique
glycosylase
xanthine
FIP1L1
Gsta2
Sult2a1
hearing
worsen
SOD
p-fluoro
INR
neuroendocrine
C6
CCl(4)
TAS2R16
blocks
innately
newly
consumed
-71
therefore
limited
VEGF
RR
generally
relations
rIFNa-2b
butyrate
aminoglycoside
displays
monkeys
mimicked
Mitochondrial
rhesus
diflunisal
predilection
how
ESR1
Maxdrinks
ciclosporin
secondly
gamma-carboxyglutamic
Diagnostic
DHPG
CHEK2
HGF
cis-platinum
flu
PepT1
C825T
follicles
sessions
rs11076161
XPA
rs9332127
amprenavir
adjust
.49
NMR
PegIFN
MUC1
generates
Glutathione
arterial
carcinogenesis
hypomethylation
intermediate
tachyarrhythmia
By
Collies
remodeling
shell
centromedial
FAK
1.7-43
Animal
enrolled
ALDH1b1
polymerase-1
time-dependent
animal
Poly(ADP-ribose)
More
Hepatoprotective
fourfold
CNR1
triggered
Arg194Trp
levamisole
autochthonous
hemachromatosis
ACh
OEA
C303
G1
[C-X-C
Imiquimod
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
MPTP
TH
123
-hydroxylase
selectively
parkinsonian
Parkinson
S9
His95Arg
neurotoxin
GISTs
Most
adenocarcinoma
favored
P1635
23.6
stimulation-
microinjection
free
CDK9
Cyclin-dependent
delivery
IRENE
composed
-37C-->A
ectopic
endpoints
simvastatin
omeprazole
symptom
Individual
caudate/nucleus
FSHR
donors
17-(beta-D-glucuronide
BI-TK
163.6
rs2619539
Available
313
.00003
HRT1B
P1635-
GALR1
widely
discovery
mGlu3
antibiotics
-1639
G>A
manifestations
therapeutics
breakdown
identifies
Taq1
individualization
light
brain-derived
RIalpha
Val(660)Leu
nonsmall
rs7089580
1236C>T
.69
-terminally
considerably
chorea
ACC
Multitest
8.48
-abuse
proteoliposomes
shunting
c-
equal
CONCLUSIONS/SIGNIFICANCE
14.17
susceptible
BSS
-116C/G
factor-alpha
high-density
751Lys
IVF
P-TEFb
sought
inter-patient
Ph
Network
attenuated
-infected
Alleles
100-240
94C>A
48
probucol
event-related
neuroprotective
3-fold
identical
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
endoxifen
nonlinear
NAA
-controlled
0024
R184S
mesoderm
0.264
pantoprazole
enantioselective
cosegregates
Compound
Omacetaxine
online
requiring
Body
antigens
54
/Met
40-250
atypical
GZD824
Dopamine
IBD
SAQUINAVIR
inducers
MOCOS
bound
ALOX5
CB
metabolite
interfered
Variation
declined
F1
Scientific
NAT1
DR5
toxicology
infarction
-16
C3435Tpolymorphism
IIA
AZD1152-HQPA
6477-6763
pegylated-interferon
-inducible
pPVN
MOR
TAG
access
rs307826
MZ
MN
surgery
subacute
FQI
L2/L3
AMH
0.033
infertility
transglutaminase
non-R/R
1.27
Taq1A
NJ
I/D
luciferase
fluoropyrimidine
mmol/l
loop
conventional
3H1
MK-801
set
culture
22.5
largely
magnetic
Substituting
requirement
E-3174
POLG
alpha-hydroxymetoprolol
Adenoma
intracerebroventricular
A2A
hand
key
positivity
dimethylarsinic
hydrochloride
/AML
co-occurring
HRQoL
Major
NVP
-tranferases
every
-scanning
deaminase-like
doi
PANSS
investigates
flow
ASMF
Ch17CEP
-stimulated
GS-9219
0.19
immunoassays
hepatotoxic
Latex
Temsirolimus
SULT1A1
functions
column
withdrawn
non-carriers
competitive
Brca2
granted
modulation
rs7687423
globulin
Prognostic
PNA-AAV8
schizoaffective
incentive
1.0-7
J129
May
Exposure
PC12
ABCC8
episode
PDGFR-a
1.16
height
loricrin
effluxed
60-mmol/L
rhodamine
nutlin-3
p-fluorofentanyl
genetics
commenced
modifier
Ins
postoperative
Gly
modulated
TCA-b
CR
reducing
Sequence
68
CoCl2
0.15
cirrhotic
I399
interfere
125I
0.11
0.54
Selective
double
NME1
down-regulation
BCL2L12
posaconazole
322-325
PNA
L-DOPA
converging
7alpha-hydroxylase
interactive
47His
gastrointestinal
electrogenetherapy
rs2228093
regulators
HTR3B
2.8
rabbit
typing
individually
unnoticed
FCGR3A
lymphocyte
antithymocyte
monitored
reinstatement
rs2630578
faster
orlistat
graft
phosphoribosyltransferase
3'-azido-3'-deoxythymidine
discrete
comorbid
2.0
b-catenin
experiment
.6
Her-2
1.25
SAHA
EGC
r-ATG
1F
3.64
p.R144C
comparing
1-month
47/376
bacterial
TNF-b
-mimicking
Particularly
insertion
fell
TLR4
arms
soon
about
PDLIM5
NPC1L1
MM6
37/61
T369I
emerged
argues
CYP3a13
decisions
olanzapine
12.5
pSTAT3
TCA
radiosensitizer
WY14,643
BAX
Evodiamine
nic
NSCLCs
0.622
Del
airways
pectenotoxin-2
actions
areas
latter
7.2
nM
EC50
CiVDR/PXRa
rs11676382
Thiopurine
Implementation
CPIC
Haloperidol
4-hydroxy-tamoxifen
L180M
Clinical
guidelines
cost-effective
left
0.75
1.75
0.49
multilineage
hydrogen
3.83
nonischemic
DTH
1000
0.792
-adrenergic
0.50
Arg389Gly-
glia
(HCV)
consolidated
motif]
Salmeterol
KEY
impair
fisetin
AC0010
c.2677G>T
Drd2
instead
thermolabile
micromol/L
beyond
-exposed
Y
hydrolase
entire
Within
arachidonate
biguanides
cytosine
fluticasone
charantia
-QD
sensation
a-glucosidase
comparative
Herceptin
BH4
*347_*348insA
1.39
true
RGS3
Homocysteine
nonresponders
ecstasy
distant
N40D
0.95
Transfer
synergistic
type-1
EMID2
rs1799978
molecule-1
corticosteroids
determinant
antialcoholism
Hepatic
nateglinide
TRAG-3
give
infarct
0.049
representative
South
overview
disulfiram
xanthone
crozotinib
38
disulfide
valerenic
nonfunctional
Preclinical
confirmation
ICAM-1
Ig
RECIST
Cu
lacking
tetracycline
generate
+14.4
methylated
Immunoglobulin
Ester
CyclinB1
FPG
PMF
deficiencies
magnitude
Protein
benefiting
6-month
sulphonylurea
DFMO
7-days
episodes
MS
KCNQ1
well-tolerated
Cholesteryl
treating
AM251
+7.2
mEH
beta-fibrinogen
TaqI
+13.8
Stromelysin-1
MiaPaca2
GnRH
apoE4
sharply
RT-PCR
relapses
T69N
silymarin
healthy-volunteer
PROC
